Robert G. Ramsay
YOU?
Author Swipe
View article: CREB: A multifaceted transcriptional regulator of neural and immune function in CNS tumors
CREB: A multifaceted transcriptional regulator of neural and immune function in CNS tumors Open
Cancers of the central nervous system (CNS) are unique with respect to their tumor microenvironment. Such a status is due to immune-privilege and the cellular behaviors within a highly networked, neural-rich milieu. During tumor developmen…
View article: Supplementary Figure 3 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure 3 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure 3. MybPlt4 exacerbates hematopoietic defects in ApcMin/+ mice.
View article: Supplementary Data Legends from Antagonism of IAPs Enhances CAR T-cell Efficacy
Supplementary Data Legends from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Supplementary data legends
View article: Data from Antagonism of IAPs Enhances CAR T-cell Efficacy
Data from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B-cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poo…
View article: Supplementary Figure 3 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure 3 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure 3. MybPlt4 exacerbates hematopoietic defects in ApcMin/+ mice.
View article: Supplementary Figure 2 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure 2 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure 2. Myb, TCF-4, and E2F-1 binding sites identified within the human CCNE1 promoter region.
View article: Movie 1 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Movie 1 from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Movie S1
View article: Movie 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Movie 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Movie S2
View article: Supplementary Figure 1 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure 1 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure 1. Myb, TCF-4, and E2F-1 binding sites identified within the murine Cyclin E1 promoter region.
View article: Data from Antagonism of IAPs Enhances CAR T-cell Efficacy
Data from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B-cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poo…
View article: Supplementary Figures 1 and 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Supplementary Figures 1 and 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Figures S1 and S2
View article: Movie 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Movie 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Movie S2
View article: Data from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Data from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Cyclin E1 is essential for the reentry of quiescent cells into the cell cycle. When hypomorphic mutant Myb mice (MybPlt4) were examined, it was noted that Cyclin E1 (Ccne1) expression was reduced. Furthermore, the induction of Ccne1 in rec…
View article: Supplementary Figure 2 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure 2 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure 2. Myb, TCF-4, and E2F-1 binding sites identified within the human CCNE1 promoter region.
View article: Supplementary Figures 1 and 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Supplementary Figures 1 and 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Figures S1 and S2
View article: Supplementary Figure Legends from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure Legends from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure Legends
View article: Movie 1 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Movie 1 from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Movie S1
View article: Supplementary Figure Legends from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure Legends from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure Legends
View article: Supplementary Figure 1 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Supplementary Figure 1 from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Supplementary Figure 1. Myb, TCF-4, and E2F-1 binding sites identified within the murine Cyclin E1 promoter region.
View article: Data from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis
Data from Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis Open
Cyclin E1 is essential for the reentry of quiescent cells into the cell cycle. When hypomorphic mutant Myb mice (MybPlt4) were examined, it was noted that Cyclin E1 (Ccne1) expression was reduced. Furthermore, the induction of Ccne1 in rec…
View article: Supplementary Data Legends from Antagonism of IAPs Enhances CAR T-cell Efficacy
Supplementary Data Legends from Antagonism of IAPs Enhances CAR T-cell Efficacy Open
Supplementary data legends
View article: Figure S5 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Figure S5 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Extended peritonoid drug sensitivity data
View article: Data from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Data from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 Open
Purpose: The major cause of morbidity in breast cancer is development of metastatic disease, for which few effective therapies exist. Because tumor cell dissemination is often an early event in breast cancer progression and can occur befor…
View article: Supplementary Figure 3 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Supplementary Figure 3 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 Open
PDF file - 159K, Supplementary Figure 3. BMTP78 kills breast cell lines in a GRP78-dependent manner.
View article: Supplementary Figure 1 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Supplementary Figure 1 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 Open
PDF file - 735K, Supplementary Figure 1. Details of the analysis of cell surface GRP78 levels using flow cytometry.
View article: Supplementary Figure 5 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Supplementary Figure 5 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 Open
PDF file - 425K, Supplementary Figure 5. Body weights of mice bearing 4T1.2 mammary tumors during treatment with BMTP78 or control peptide or saline.
View article: Supplementary Methods from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Supplementary Methods from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy Open
Supplementary Methods
View article: Supplementary Figure 3 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78
Supplementary Figure 3 from Inhibition of Established Micrometastases by Targeted Drug Delivery via Cell Surface–Associated GRP78 Open
PDF file - 159K, Supplementary Figure 3. BMTP78 kills breast cell lines in a GRP78-dependent manner.